Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Logo Image
Commentary|Videos|September 11, 2025

How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery

In this video interview, Adrianne Rivard, senior community development manager at myTomorrows, explains why compliance with privacy standards and physician training are critical for safe and effective use of GenAI in clinical trial discovery.

In a recent video interview with Applied Clinical Trials, Adrianne Rivard, senior community development manager, myTomorrows, discussed the challenges physicians face in identifying clinical trials. Highlighting insights from a recent myTomorrows report on the need to streamline clinical operations, Rivard touched on the use of artificial intelligence (AI) to streamline pre-screening, which can reduce the need for multiple databases. She also discussed how AI tools are gaining use, necessitating compliance with data privacy standards and ongoing education to build trust among physicians.

ACT: With nearly a third of physicians now using GenAI tools like ChatGPT to aid in trial discovery, how should clinops teams evaluate and validate the accuracy, compliance, and usability of these emerging technologies?

Rivard: It's great to hear that physicians are starting to use GenAI tools, because I think, like everyone else, they had their initial uncertainty of AI. ‘Can I use this? Can I trust this? How does this work?’ I think especially because physicians are using sensitive data, it's good that they're cautious, but I think for anyone using the tools, or encouraging people to use the tools, really need to make sure that they comply with data privacy standards, regulatory frameworks like HIPAA and GDPR. I think another key factor is education, and we also saw this from the survey, that 69% of physicians said that actual training would build better confidence and trust in the AI, so I think providing ongoing education and support is just as important as the technology itself.

Related to this article

View more
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Read more
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Read more
Where AI Governance in Clinical Development Falls Short
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
Read more
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
Read more